MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.105
-0.165
-12.99%
Opening 09:49 08/06 EDT
OPEN
1.100
PREV CLOSE
1.270
HIGH
1.150
LOW
1.090
VOLUME
3.96M
TURNOVER
--
52 WEEK HIGH
1.970
52 WEEK LOW
0.4000
MARKET CAP
49.93M
P/E (TTM)
-1.7263
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CTXR stock price target is 5.50 with a high estimate of 7.00 and a low estimate of 4.000.

EPS

CTXR News

More
Citius Submits Mino-Wrap Briefing Package To FDA For Pre-IND Consult
CRANFORD, N.J., Aug. 4, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and
Benzinga · 2d ago
Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19
Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today the formation of the Citius ARDS (Acute Respiratory Distress Syndrome)
PR Newswire · 07/22 14:30
Citius Pharmaceuticals to Present at the MoneyShow Accredited Investor Virtual Event
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the company will deliver a presentation at the MoneyShow Acc
PR Newswire · 07/20 18:00
Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that Myron S. Czuczman, M.D., has joined the company as Chief Med
PR Newswire · 07/14 12:47
Citius Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
Benzinga · 07/13 12:16
MFGP, WKHS among premarket losers
Seeking Alpha - Article · 07/07 12:12
Citius Pharmaceuticals (CTXR) Jumps: Stock Rises 5.1%
Zacks · 06/30 13:54
MU, SPG among premarket gainers
Seeking Alpha - Article · 06/30 12:21

Industry

Biotechnology & Medical Research
+0.10%
Pharmaceuticals & Medical Research
+0.25%

Hot Stocks

Symbol
Price
%Change

About CTXR

Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is focused on developing and commercializing care products with a focus on anti-infective products in adjunct cancer care and prescription products. It has three product candidates: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). Mino-Lok product is designed to salvage the central venous catheters CVC, obviating the need to remove and replace the catheter. Mino-Wrap is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. CITI-002 is being developed for symptomatic relief of hemorrhoids. CITI-002 combines the steroid, halobetasol, with lidocaine.
More

Webull offers kinds of Citius Pharmaceuticals Inc stock information, including NASDAQ:CTXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTXR stock methods without spending real money on the virtual paper trading platform.